Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Advanced imaging, such as PET scans, are beginning to show the ability to diagnose Alzheimer’s dementia in people with early ...

The females in my family on my mother's side seem to develop dementia/Alzheimer's on a fairly regular basis. It seems to ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai presented the latest findings on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC), held in Toronto, ...